The cerebral infarction treatment market size has grown strongly in recent years. It will grow from $11.05 billion in 2024 to $11.84 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth during the historic period can be attributed to higher healthcare expenditure, an increase in hospital admissions, a rise in minimally invasive stroke procedures, growing demand for mechanical thrombectomy devices, and an expansion in clinical trials.
The cerebral infarction treatment market size is expected to see strong growth in the next few years. It will grow to $15.54 billion in 2029 at a compound annual growth rate (CAGR) of 7%. The projected growth in the forecast period can be attributed to the expanding geriatric population, a rising prevalence of stroke, an increase in cerebrovascular and cardiovascular diseases, and a growing incidence of cerebral infarction. Key trends expected during this period include the integration of telemedicine, the use of wearable health monitoring devices, advancements in neuroimaging techniques, the adoption of robotic-assisted surgery, nanotechnology-based drug delivery systems, and the development of virtual rehabilitation platforms.
The rising prevalence of stroke is anticipated to drive the growth of the cerebral infarction treatment market in the coming years. A stroke occurs when blood flow to the brain is disrupted or blocked, leading to a deficiency of oxygen and nutrients in brain tissue. This increase in stroke cases is largely attributed to the growing incidence of hypertension, which damages blood vessels and contributes to stroke risk. Cerebral infarction treatments play a crucial role in stroke care by restoring cerebral blood flow, minimizing long-term damage and disability. These treatments enhance patient outcomes through timely medical intervention, resulting in more effective and manageable recovery. For example, in September 2024, the Stroke Foundation, an Australia-based not-for-profit organization, reported that Australia experienced 45,785 stroke cases in 2023, with projections indicating a significant increase to 72,000 cases by 2050. Thus, the growing prevalence of stroke is a key factor fueling the expansion of the cerebral infarction treatment market.
Leading companies in the cerebral infarction treatment market are prioritizing the development of advanced technologies, such as dual aspiration technology, to reduce treatment time for patients with acute ischemic stroke. Dual aspiration technology involves the simultaneous use of two catheters to improve the efficiency of clot removal during stroke interventions. For example, in May 2025, Imperative Care, a U.S.-based medical technology company, introduced Zoom DuoPort, a cutting-edge stroke treatment device. This system supports dual aspiration by allowing two catheters to function concurrently with a single vacuum source. It enhances physician control, offers real-time procedural feedback, and increases the effectiveness of mechanical thrombectomy in treating acute ischemic stroke.
In March 2025, Medtronic plc, an Ireland-based medical device company, formed a partnership with Methinks AI to incorporate AI-powered stroke detection software into its neurovascular care solutions. The collaboration is intended to improve early stroke diagnosis, optimize triage processes, and enhance treatment outcomes, particularly in underserved areas. Methinks AI, a digital health company based in Spain, specializes in developing artificial intelligence solutions for the diagnosis and management of stroke.
Major players in the cerebral infarction treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Bayer AG, Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Novartis AG, Medtronic plc, Amgen Inc., Siemens Healthineers, Becton, Dickinson and Company, Stryker Corporation, Boston Scientific Corporation, Daiichi Sankyo Company Limited, Penumbra Inc., Terumo Corporation, phenox GmbH, Boehringer Ingelheim International GmbH, Imperative Care Inc., Acandis GmbH & Co. KG, Reflow Medical Inc., Lumosa Therapeutics Inc., Insera Therapeutics Inc., Q’Apel Medical Inc.
North America was the largest region in the cerebral infarction treatment market in 2024. The regions covered in cerebral infarction treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the cerebral infarction treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Cerebral infarction treatment involves medical interventions designed to restore blood flow to the brain and limit the damage caused by a stroke resulting from blocked blood vessels (ischemic stroke). The primary goal of this treatment is to prevent additional brain injury, reduce neurological impairments, and enhance patient recovery.
The core types of treatment for cerebral infarction include medications, surgical procedures, and rehabilitation therapies. Medications used in this context aim to dissolve blood clots, regulate blood pressure, and prevent future strokes. Diagnostic methods employed in treatment consist of computed tomography (CT) scans, magnetic resonance imaging (MRI), angiography, and Doppler ultrasound. The treatment is applied to conditions such as ischemic stroke, transient ischemic attack, large artery stroke, and small vessel stroke, with end-users including hospitals, dedicated stroke centers, ambulatory surgical centers, and home care services.
The cerebral infarction treatment market research report is one of a series of new reports that provides cerebral infarction treatment market statistics, including cerebral infarction treatment industry global market size, regional shares, competitors with a cerebral infarction treatment market share, detailed cerebral infarction treatment market segments, market trends and opportunities, and any further data you may need to thrive in the cerebral infarction treatment industry. This cerebral infarction treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cerebral infarction treatment market consists of revenues earned by entities by providing services such as thrombolytic therapy administration, surgical interventions, rehabilitation programs, diagnostic imaging, and post-treatment patient care and monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The cerebral infarction treatment market also includes sales of anticoagulants, antiplatelet agents, thrombolytics, neuroprotective drugs, as well as medical devices such as stents, catheters, and diagnostic imaging equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The cerebral infarction treatment market size is expected to see strong growth in the next few years. It will grow to $15.54 billion in 2029 at a compound annual growth rate (CAGR) of 7%. The projected growth in the forecast period can be attributed to the expanding geriatric population, a rising prevalence of stroke, an increase in cerebrovascular and cardiovascular diseases, and a growing incidence of cerebral infarction. Key trends expected during this period include the integration of telemedicine, the use of wearable health monitoring devices, advancements in neuroimaging techniques, the adoption of robotic-assisted surgery, nanotechnology-based drug delivery systems, and the development of virtual rehabilitation platforms.
The rising prevalence of stroke is anticipated to drive the growth of the cerebral infarction treatment market in the coming years. A stroke occurs when blood flow to the brain is disrupted or blocked, leading to a deficiency of oxygen and nutrients in brain tissue. This increase in stroke cases is largely attributed to the growing incidence of hypertension, which damages blood vessels and contributes to stroke risk. Cerebral infarction treatments play a crucial role in stroke care by restoring cerebral blood flow, minimizing long-term damage and disability. These treatments enhance patient outcomes through timely medical intervention, resulting in more effective and manageable recovery. For example, in September 2024, the Stroke Foundation, an Australia-based not-for-profit organization, reported that Australia experienced 45,785 stroke cases in 2023, with projections indicating a significant increase to 72,000 cases by 2050. Thus, the growing prevalence of stroke is a key factor fueling the expansion of the cerebral infarction treatment market.
Leading companies in the cerebral infarction treatment market are prioritizing the development of advanced technologies, such as dual aspiration technology, to reduce treatment time for patients with acute ischemic stroke. Dual aspiration technology involves the simultaneous use of two catheters to improve the efficiency of clot removal during stroke interventions. For example, in May 2025, Imperative Care, a U.S.-based medical technology company, introduced Zoom DuoPort, a cutting-edge stroke treatment device. This system supports dual aspiration by allowing two catheters to function concurrently with a single vacuum source. It enhances physician control, offers real-time procedural feedback, and increases the effectiveness of mechanical thrombectomy in treating acute ischemic stroke.
In March 2025, Medtronic plc, an Ireland-based medical device company, formed a partnership with Methinks AI to incorporate AI-powered stroke detection software into its neurovascular care solutions. The collaboration is intended to improve early stroke diagnosis, optimize triage processes, and enhance treatment outcomes, particularly in underserved areas. Methinks AI, a digital health company based in Spain, specializes in developing artificial intelligence solutions for the diagnosis and management of stroke.
Major players in the cerebral infarction treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Bayer AG, Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Novartis AG, Medtronic plc, Amgen Inc., Siemens Healthineers, Becton, Dickinson and Company, Stryker Corporation, Boston Scientific Corporation, Daiichi Sankyo Company Limited, Penumbra Inc., Terumo Corporation, phenox GmbH, Boehringer Ingelheim International GmbH, Imperative Care Inc., Acandis GmbH & Co. KG, Reflow Medical Inc., Lumosa Therapeutics Inc., Insera Therapeutics Inc., Q’Apel Medical Inc.
North America was the largest region in the cerebral infarction treatment market in 2024. The regions covered in cerebral infarction treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the cerebral infarction treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Cerebral infarction treatment involves medical interventions designed to restore blood flow to the brain and limit the damage caused by a stroke resulting from blocked blood vessels (ischemic stroke). The primary goal of this treatment is to prevent additional brain injury, reduce neurological impairments, and enhance patient recovery.
The core types of treatment for cerebral infarction include medications, surgical procedures, and rehabilitation therapies. Medications used in this context aim to dissolve blood clots, regulate blood pressure, and prevent future strokes. Diagnostic methods employed in treatment consist of computed tomography (CT) scans, magnetic resonance imaging (MRI), angiography, and Doppler ultrasound. The treatment is applied to conditions such as ischemic stroke, transient ischemic attack, large artery stroke, and small vessel stroke, with end-users including hospitals, dedicated stroke centers, ambulatory surgical centers, and home care services.
The cerebral infarction treatment market research report is one of a series of new reports that provides cerebral infarction treatment market statistics, including cerebral infarction treatment industry global market size, regional shares, competitors with a cerebral infarction treatment market share, detailed cerebral infarction treatment market segments, market trends and opportunities, and any further data you may need to thrive in the cerebral infarction treatment industry. This cerebral infarction treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cerebral infarction treatment market consists of revenues earned by entities by providing services such as thrombolytic therapy administration, surgical interventions, rehabilitation programs, diagnostic imaging, and post-treatment patient care and monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The cerebral infarction treatment market also includes sales of anticoagulants, antiplatelet agents, thrombolytics, neuroprotective drugs, as well as medical devices such as stents, catheters, and diagnostic imaging equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Cerebral Infarction Treatment Market Characteristics3. Cerebral Infarction Treatment Market Trends And Strategies4. Cerebral Infarction Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market32. Global Cerebral Infarction Treatment Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Cerebral Infarction Treatment Market34. Recent Developments In The Cerebral Infarction Treatment Market
5. Global Cerebral Infarction Treatment Growth Analysis And Strategic Analysis Framework
6. Cerebral Infarction Treatment Market Segmentation
7. Cerebral Infarction Treatment Market Regional And Country Analysis
8. Asia-Pacific Cerebral Infarction Treatment Market
9. China Cerebral Infarction Treatment Market
10. India Cerebral Infarction Treatment Market
11. Japan Cerebral Infarction Treatment Market
12. Australia Cerebral Infarction Treatment Market
13. Indonesia Cerebral Infarction Treatment Market
14. South Korea Cerebral Infarction Treatment Market
15. Western Europe Cerebral Infarction Treatment Market
16. UK Cerebral Infarction Treatment Market
17. Germany Cerebral Infarction Treatment Market
18. France Cerebral Infarction Treatment Market
19. Italy Cerebral Infarction Treatment Market
20. Spain Cerebral Infarction Treatment Market
21. Eastern Europe Cerebral Infarction Treatment Market
22. Russia Cerebral Infarction Treatment Market
23. North America Cerebral Infarction Treatment Market
24. USA Cerebral Infarction Treatment Market
25. Canada Cerebral Infarction Treatment Market
26. South America Cerebral Infarction Treatment Market
27. Brazil Cerebral Infarction Treatment Market
28. Middle East Cerebral Infarction Treatment Market
29. Africa Cerebral Infarction Treatment Market
30. Cerebral Infarction Treatment Market Competitive Landscape And Company Profiles
31. Cerebral Infarction Treatment Market Other Major And Innovative Companies
35. Cerebral Infarction Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Cerebral Infarction Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on cerebral infarction treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cerebral infarction treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cerebral infarction treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Treatment Type: Medication; Surgical Interventions; Rehabilitation Therapies2) By Diagnostic Tools: Computed Tomography Scan; Magnetic Resonance Imaging; Angiography; Doppler Ultrasound
3) By Application: Ischemic Stroke; Transient Ischemic Attack; Large Artery Stroke; Small Vessel Stroke
4) By End-User: Hospitals; Specialized Stroke Centers; Ambulatory Surgical Centers; Home Care Providers
Subsegments:
1) By Medication: Antiplatelet Drugs; Anticoagulants; Thrombolytics; Statins; Antihypertensives2) By Surgical Interventions: Mechanical Thrombectomy; Carotid Endarterectomy; Decompressive Craniectomy; Stent Placement; Angioplasty
3) By Rehabilitation: Physical Therapy; Occupational Therapy; Speech and Language Therapy; Cognitive Rehabilitation; Psychological Counseling
Key Companies Profiled: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche AG; Bayer AG; Sanofi S.A.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc.
- Johnson & Johnson
- F. Hoffmann-La Roche AG
- Bayer AG
- Sanofi S.A.
- AstraZeneca plc
- Abbott Laboratories
- Novartis AG
- Medtronic plc
- Amgen Inc.
- Siemens Healthineers
- Becton, Dickinson and Company
- Stryker Corporation
- Boston Scientific Corporation
- Daiichi Sankyo Company Limited
- Penumbra Inc.
- Terumo Corporation
- phenox GmbH
- Boehringer Ingelheim International GmbH
- Imperative Care Inc.
- Acandis GmbH & Co. KG
- Reflow Medical Inc.
- Lumosa Therapeutics Inc.
- Insera Therapeutics Inc.
- Q’Apel Medical Inc.